Enjoy complimentary customisation on priority with our Enterprise License!
The recombinant proteins market size is estimated to increase by USD 778.50 million and grow at a CAGR of 10.23% between 2023 and 2028. Market growth hinges on several factors, notably the upsurge in chronic diseases, a growing preference for biologics and biosimilars, and advancements in the technology employed for recombinant protein production. However, challenges persist, encompassing complexities in manufacturing and storage, coupled with high costs, alongside the increasing popularity of alternative treatments and the intricate regulatory landscape. With these conditions becoming increasingly prevalent worldwide, there's a heightened demand for advanced therapeutics and treatments, many of which rely on recombinant proteins for effective management. Investments in research and development play a crucial role in driving innovation, leading to the introduction of novel recombinant protein-based therapies to address evolving medical needs.
To learn more about this report, View Report Sample
The market share growth by the biotechnology research segment will be significant during the forecast period. The broad field of biotechnology involves the use of biological processes, animals, cells, or cell components to develop new technologies. They have contributed to significant advances in biomedical biotechnology. More and more recombinant proteins are being used in laboratories. This includes proteins generated in course-specific research projects as well as commercially available proteins (such as most enzymes used in molecular biology laboratories). Recombinant lysosomal proteins are often made by mammalian cells. FDA-approved glycosylated lysosomal protein drugs and other drug candidates were developed using plant cell culture. Recombinant lysosomal proteins can be produced using microorganisms such as Saccharomyces cerevisiae and Escherichia coli. There are both scientific and medical uses for recombinant lysosomal proteins, including enzyme replacement therapy. Such factors drive the growth of the market during the forecast period.
Get a glance at the market contribution of various segments View the PDF Sample
The biotechnology research segment was valued at USD 451.40 million in 2018. They are a useful resource for understanding how proteins interact with each other. They have demonstrated their efficacy in various laboratory tests such as ELISA, Western blot, and immunohistochemistry (IHC). Enzymatic assays can be created using recombinant proteins. They are also used in food production, agriculture, and biotechnology. In addition, researchers have used genetic techniques to modify proteins to create recombinant therapeutic proteins. In general, the development of biotechnology has facilitated the production for various applications. Such factors drive the growth of the market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The market in the North American region is growing rapidly due to the higher uptake. The major driving force for the market in this region is the increasing prevalence of cancer, autoimmune diseases, metabolic diseases, musculoskeletal diseases, central nervous system diseases, hematological diseases, etc. The prevalence of cardiovascular disease and cancer is increasing worldwide. Therefore, the demographic and economic growth in this region is expected to present great opportunities for the market. Factors such as rising R&D spending, increasing research activity, favorable government funding, and the presence of key players in the region are boosting the market expansion during the forecast period.
The market is advancing with significant applications across various medical fields, addressing conditions like granulomatous disease, hemophilia, and sclerosis. Emerging technologies such as recombinant technology have enabled the production of therapeutic proteins for treating metabolic disorders, genetic disorders, and immune diseases. Countries like Turkey, Colombia, Argentina, and Ukraine are pivotal in the global market, contributing to international diabetes and other health sectors. Protein based treatments produced in mammalian systems, insect cells, yeast & fungi, and bacterial cells cater to diverse therapeutic and immunological needs. The market's growth is driven by advancements in immunology and neuroscience, particularly in the therapeutics and services segments of the pharma industry, offering new avenues for combating complex diseases such as diabetes with innovative biotechnological solutions.. The Covovax vaccine is a significant advancement in the therapeutics segment of the pharma industry, offering promising protein-based treatment options within the services segment. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growth of the market is primarily propelled by an increase in chronic diseases such as cancer, cardiovascular ailments, and viral infections. As these diseases become more prevalent globally, the demand for advanced therapeutics and treatments rises, with many relying on recombinant proteins for effective management. Investments in research and development are pivotal drivers, fostering innovation and leading to the introduction of novel recombinant protein-based therapies. These investments drive the launch of advanced recombinant products, expanding the therapeutic landscape and enhancing patient care.
Furthermore, the aging population contributes significantly to the market's expansion. With a growing number of elderly individuals worldwide, there is a heightened demand for biologics and biosimilars, as older age groups are more prone to chronic ailments. This demographic shift not only increases the prevalence of chronic diseases but also underscores the importance of biologics and biosimilars in addressing age-related health challenges. Consequently, the inclination towards biologics and biosimilars escalates, further driving growth in the recombinant proteins market.
Growing opportunities from emerging economies is a key trend influencing market growth. With diverse healthcare markets, the rising prevalence of infectious and chronic diseases, and increasing R&D efforts to develop cutting-edge proteomics and genomics methods, emerging markets such as Asia offer great potential for market participants. In addition to these factors, market participants are encouraged to invest in the region of an aging population, rising income levels, improved healthcare infrastructure, rising healthcare costs, and the region's leadership in low-cost manufacturing. Asia's regulatory framework is also more flexible and business-friendly, attracting larger companies that are already struggling with stiff competition in established markets.
Additionally, governments in several emerging countries in Asia are taking steps to raise awareness of cancer and its diagnosis so that it can be detected early. For example, the health minister of the Indian state of Tamil Nadu said that the government of Tamil Nadu will help identify 66% of stage 1 and stage 2 cancer patients by 2030. He said he was working on developing policies for proper treatment. Consequently, such policies are expected to boost the growth of the market during the forecast period.
A complicated regulatory framework is challenging market growth. Obtaining regulatory approval is often difficult, unpredictable, and subjective. Recombinant proteins are subject to extensive and stringent regulations before approval and commercialization. From a global perspective, the United States currently lags behind other regulated markets, particularly the European Union (EU), in the biosimilar race. The US biosimilar industry continues to attract attention despite the lack of new entrants. The first and most important factor expected to determine the future of biosimilars in the United States has to do with the approval of the regulatory framework within which biosimilar developers must operate.
In Europe, strict regulations are applied to ensure their safety and effectiveness in protecting people. However, most European countries have good market traction as the approval process is a bit faster than in the US. The inability of a provider to provide clinical data showing positive results in a particular region can incur costs, create uncertainty, and confound other studies. This may create barriers for vendors to develop new protein therapeutics in the market and may adversely affect the growth of the market during the forecast period.
The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Abcam plc: The company is involved in the production, distribution, and sales of antibodies and protein research tools. It also offers different types of recombinant proteins, such as bioactive grade proteins and others.
The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Protein Expression Market: Protein Expression Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, China, Germany, Japan - Size and Forecast
Proteomics Market: Proteomics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, UK, Germany, China, Japan - Size and Forecast
Protein Therapeutics Market: Protein Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
The market is pivotal in biopharmaceuticals, offering solutions for rare genetic diseases and addressing global health challenges like the SARS-CoV2 virus with vaccines such as Covovax. Biopharmaceuticals play a crucial role in developing protein-based treatments for conditions such as HIV/AIDS, Alzheimer's disease, and dementia, utilizing biomarkers and innovative research in protein production. Ayvakit targets the KIT D816V mutation in cancers like leukemia, underscoring advancements in therapeutics and services segments. Research funding and R&D budgets fuel progress in biopharma and vaccination measures, benefiting diverse populations including the Mexican population. Technologies like phage vectors, host cell lines, and gene libraries enhance antibody production, driving the market's expansion in global healthcare initiatives and American Cancer research efforts.
Market Scope |
|
Report Coverage |
Details |
Page number |
178 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.23% |
Market growth 2024-2028 |
USD 778.5 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
9.37 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 36% |
Key countries |
US, China, Germany, Italy, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abcam plc, Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Bio Techne Corp., Bio Rad Laboratories Inc., BPS Bioscience Inc., Elabscience Biotechnology Inc., Enzo Biochem Inc., GenScript Biotech Corp., Grifols SA, Merck KGaA, Novartis AG, Novo Nordisk AS, OriGene Technologies Inc., Prospec Tany Technogene Ltd., Proteintech Group Inc., Sanofi SA, Sino Biological Inc., and Thermo Fisher Scientific Inc. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, Market growth and Forecasting, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.